Collaborative Arrangements (Details 5) (Development and Commercialization Agreement, R-Pharm CJSC, USD $)	0 Months Ended	1 Months Ended
	Oct. 31, 2012	Oct. 31, 2012 Item
Information related to collaborative arrangements
Number of development and commercialization agreements	2	2
Maximum
Information related to collaborative arrangements
Potential future contingent payments receivable	$ 10,000,000	$ 10,000,000
VIBATIV
Information related to collaborative arrangements
Upfront payment		1,100,000
Royalty rate, as a percentage of net sales	25.00%
Upfront payment received allocated to license		1,000,000
Upfront payment received allocated to committee participation		33,000
Number of units of accounting based on the relative selling price method		2
TD-1792
Information related to collaborative arrangements
Upfront payment		1,100,000
Royalty rate, as a percentage of net sales	15.00%
Upfront payment received allocated to license		900,000
Upfront payment received allocated to committee participation		$ 100,000
Number of units of accounting based on the relative selling price method		2